Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Operating Expenses (2016 - 2025)

Vanda Pharmaceuticals' Operating Expenses history spans 16 years, with the latest figure at $97.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 53.74% year-over-year to $97.6 million; the TTM value through Dec 2025 reached $367.3 million, up 53.39%, while the annual FY2025 figure was $367.3 million, 53.39% up from the prior year.
  • Operating Expenses for Q4 2025 was $97.6 million at Vanda Pharmaceuticals, up from $87.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $97.6 million in Q4 2025 and bottomed at $44.8 million in Q3 2023.
  • The 5-year median for Operating Expenses is $59.9 million (2021), against an average of $64.4 million.
  • The largest annual shift saw Operating Expenses dropped 27.03% in 2023 before it surged 60.62% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $59.4 million in 2021, then decreased by 2.58% to $57.9 million in 2022, then fell by 9.49% to $52.4 million in 2023, then grew by 21.2% to $63.5 million in 2024, then soared by 53.74% to $97.6 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Operating Expenses are $97.6 million (Q4 2025), $87.5 million (Q3 2025), and $91.1 million (Q2 2025).